Hyderabad: Pharma major Dr. Reddy’s Laboratories Ltd announced on Wednesday that it has entered into a royalty-free, non-exclusive voluntary license agreement with Eli Lilly and Company for the manufacture and commercialization of Baricitinib in India.
The drug baricitinib has received limited emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This partnership reaches a critical point in the fight against the pandemic in India and contributes to the existing series COVID-19 therapy that covers the whole spectrum from mild to moderate and severe illnesses and a vaccine, the company said in Hyderabad.
‘We have been determined from the outset to explore every possible path COVID-19. Our collaboration with Lilly will help us make another treatment option available to patients in India, ‘says Deepak Sapra, CEO, API and Services, Dr. Reddy’s Laboratories.
In another development, Dr Reddy’s announced the launch of Ertapenem for Injection, 1 g / vial, a therapeutically equivalent generic version of INVANZ (ertapenem for injection), 1 g / vial, approved by the US Food and Drug Administration Drug Administration (USFDA).
“We are pleased to launch this important product at this time,” said Marc Kikuchi, CEO of North America Generics, Dr. Reddy’s Laboratories. “We are delighted to expand our strategic partnership with Gland Pharma, whose hard work, in collaboration with Dr. Reddy’s team, has made the launch of this launch possible.”
‘We are delighted with this collaboration, as it Bringing together Reddy’s experienced marketing and distribution capabilities and Gland Pharma’s robust development and manufacturing capabilities. Gland Pharma has an exclusive API supply arrangement for this product and a dedicated manufacturing facility in Hyderabad for Ertapenem injection. With the launch of this product, we are seeing an increased capacity utilization of this dedicated Penem plant, ‘says Srinivas Sadu, Managing Director and CEO of Gland Pharma Ltd.
Source: The Siasat Daily